PT - JOURNAL ARTICLE AU - Yoshifumi Uwamino AU - Masatoshi Wakui AU - Yoko Yatabe AU - Terumichi Nakagawa AU - Akiko Sakai AU - Toshinobu Kurafuji AU - Ayako Shibata AU - Yukari Tomita AU - Masayo Noguchi AU - Akiko Tanabe AU - Tomoko Arai AU - Akemi Ohno AU - Hiromitsu Yokota AU - Shunsuke Uno AU - Wakako Yamasawa AU - Yasunori Sato AU - Mari Ikeda AU - Akihiko Yoshimura AU - Naoki Hasegawa AU - Hideyuki Saya AU - Mitsuru Murata TI - Anti-SARS-CoV-2 cellular immunity in 571 vaccinees assessed using an interferon-γ release assay AID - 10.1101/2021.12.14.21267039 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.14.21267039 4099 - http://medrxiv.org/content/early/2021/12/15/2021.12.14.21267039.short 4100 - http://medrxiv.org/content/early/2021/12/15/2021.12.14.21267039.full AB - Generation of antigen-specific memory T cells has been analyzed only for few coronavirus disease 2019 (COVID-19) vaccinees, whereas antibody titers have been serologically measured for a large number of individuals. Here, we assessed the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular immune response in a large cohort using interferon (IFN)-γ release assays (IGRAs) based on short-term whole blood culture. The study included 571 individuals who received the viral spike (S) protein-expressing BNT162b2 mRNA SARS-CoV-2 vaccine. Serum IgG titers against the receptor-binding domain (RBD) of S protein were measured. Samples of 28 vaccinees were subjected to flow cytometry analysis of T cells derived from short-term whole blood culture. IFN-γ production triggered by S antigens was observed in most individuals 8 weeks after receiving the second dose of the vaccine, indicating acquisition of T cell memory responses. The frequencies of activated T cell subsets were strongly correlated with IFN-γ levels, supporting the usability of our approach. S antigen-stimulated IFN-γ levels were weakly correlated with anti-RBD IgG titers and associated with pre-vaccination infection and adverse reactions after the second dose. Our approach revealed cellular immunity acquired after COVID-19 vaccination, providing insights regarding the effects and adverse reactions of vaccination.Competing Interest StatementThe part of the QuantiFERON SARS-CoV-2 reagents were sponsored by Qiagen K.K.-JAPAN (Tokyo, Japan).Funding StatementSupported by the Research Funds of the Keio University School of Medicine and Grant from Public Foundation of the Vaccination Research Center, Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design was approved by the Ethics Committee of Keio University School of Medicine (20200330).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.